Anatoly Langer - Concepedia

Author

Anatoly Langer

St. Michael's Hospital ORCID

Also Known As

A LANGER, A Langer, A. Langer, A.L. Langer, Anatoly Langer, Langer A, Peterson, Eric D., Simon W Rabkin

234

Publications

8.7K

Citations

H-Index

122

Concepts

All Affiliations

St. Michael's Hospital University of Toronto Canadian Heart Research Centre McMaster University University of Alberta

About

Anatoly Langer is an author at St. Michael's Hospital specializing in medicine, cardiovascular disease, and cardiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	33	73	3.8K
2	Public Health	27	47	2.5K
3	Health Sciences	7	7	372
4	Social Sciences	3	3	87
5	Applied Physiology	1	1	14

Anatoly Langer

112

Publications

8.1K

Citations

H-Index

Page 1

	Year	Citations
A Comparison of Low-Molecular-Weight Heparin with Unfractionated Heparin for Unstable Coronary Artery Disease Marc J. Cohen, Christine Demers, Enrique Gurfinkel, New England Journal of Medicine	1997	1.4K
Routine Early Angioplasty after Fibrinolysis for Acute Myocardial Infarction Warren J. Cantor, David Fitchett, Bjug Borgundvaag, New England Journal of Medicine	2009	578
Oral Glycoprotein IIb/IIIa Inhibition With Orbofiban in Patients With Unstable Coronary Syndromes (OPUS-TIMI 16) Trial Christopher P. Cannon, Carolyn H. McCabe, Robert G. Wilcox, Circulation	2000	288
Risk scores for risk stratification in acute coronary syndromes: useful but simpler is not necessarily better Andrew T. Yan, Raymond T. Yan, Mary Tan, European Heart Journal	2007	268
ST segment shift in unstable angina: pathophysiology and association with coronary anatomy and hospital outcome Anatoly Langer, Michael R. Freeman, Paul W. Armstrong Journal of the American College of Cardiology RadiologyCoronary AnatomyCardiovascular DiseaseUnstable AnginaCoronary Artery Disease	1989	215
Randomized Evaluation of the Safety and Efficacy of Enoxaparin Versus Unfractionated Heparin in High-Risk Patients With Non-ST-Segment Elevation Acute Coronary Syndromes Receiving the Glycoprotein IIb/IIIa Inhibitor Eptifibatide Shaun G. Goodman, David Fitchett, Paul W. Armstrong, Circulation	2003	199
Detection of silent myocardial ischemia in diabetes mellitus Anatoly Langer, Michael R. Freeman, Robert G. Josse, The American Journal of Cardiology Silent Myocardial IschemiaCardiovascular DiseaseDiabetesDiagnosisBlood Glucose Monitoring	1991	196
Factors influencing underutilization of evidence-based therapies in women Raffaele Bugiardini, Andrew T. Yan, Raymond T. Yan, European Heart Journal	2011	188
Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease∗∗∗∗A list of participating ESSENCE Study Group investigators may be found in N Engl J Med 1997;337:447–52. Shaun G. Goodman, Marc Cohen, Frédérique Bigonzi, Journal of the American College of Cardiology ThrombosisCardiovascular EpidemiologyCardiovascular DiseaseMedicineClinical Trials	2000	164
Contemporary Management of Dyslipidemia in High-Risk Patients: Targets Still Not Met Andrew T. Yan, Raymond T. Yan, Mary Tan, The American Journal of Medicine Contemporary ManagementMetabolic SyndromeLipid DisorderCardiovascular DiseaseHealth Policy	2006	158

Page 1